TG
CLLS

TLP Group’s Cellectis CLLS Stock Holding History

TLP Group’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,970
Closed -$96K – 282
2016
Q3 		$96K Buy
+3,970
New +$104K 0.1% 217

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TLP Group's CLLS Position: Q4 2016 in Review

TLP Group sold out of Cellectis (CLLS) in Q4 2016, closing a stake of 3,970 shares — an estimated $96K sold.

TLP Group first reported a position in CLLS in Q3 2016 and held it in 1 quarter. The position peaked at $96K in Q3 2016. 37 funds tracked by Wall St. Rank hold CLLS as of Q4 2016.

  • TLP Group reported no remaining Cellectis position as of Q4 2016 after selling out during the quarter.
  • TLP Group sold 3,970 Cellectis shares in Q4 2016, an estimated $96K.
  • TLP Group first reported a position in Cellectis in Q3 2016 and held it in 1 quarter.
  • TLP Group's Cellectis position peaked at $96K in Q3 2016.
  • 37 funds tracked by Wall St. Rank held Cellectis as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.